All materials are covered less than standard material transfer agreements. for further serological evaluation. We measured RBD and spike antibodies to the four hCoVs and SARS-CoV-2 by ELISA in samples from your same participants collected pre-pandemic (20182019) and mid-pandemic (2021), before COVID-19 vaccination. == Results == We observed over 72% seropositivity to the four hCoVs pre-pandemic. Binding antibodies improved with age to 229E and OC43, suggesting endemic circulation, while antibody levels was smooth across age groups for HKU1 and NL63. During the COVID-19 pandemic, antibodies increased significantly to the RBDs of OC43, NL63, and 229E and spikes of all four hCoVs in both SARS-CoV-2 negative and positive adolescents. Those aged 1215 years old in 2021 experienced higher antibodies to RBD and spike of OC43, NL63, and 229E than adolescents the same age in 2019, further demonstrating intense transmission of the hCoVs during the pandemic. == Conclusions == We observe a limited impact of the COVID-19 pandemic on endemic hCoV transmission. This study provides insight into co-circulation of hCoVs and SARS-CoV-2. == Supplementary Info == The online version consists of supplementary material available at 10.1186/s12879-024-09672-8. Keywords:Endemic coronaviruses, Seroprevalence, Philippines, COVID-19, SARS-CoV-2, OC43, HKU1, 229E, NL63 == Background == During the past 2 decades there have been three major coronavirus spillovers. The severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) pandemic from Rabbit polyclonal to IFFO1 2002 to 2004 and repeated Middle East respiratory syndrome Ac2-26 coronavirus (MERS-CoV) outbreaks since 2012 were brought under control by mitigation steps. A large number of SARS-related coronaviruses have been found out in bats, their natural reservoir host, and SARS-CoV-2 emerged on December 31, 2019 [1] resulting in over 770 million instances and Ac2-26 7 million deaths globally [2]. Lockdowns and additional measures were implemented in the spring of 2020 and highly effective vaccines were rapidly developed and deployed starting in late 2020. Despite these attempts, SARS-CoV-2 will likely continue to circulate endemically in human being populations, undergoing antigenic development in different areas with variants growing under immune selective pressure [3]. Before the intro of SARS-CoV-1, SARS-CoV-2, and MERS-CoV, four additional coronaviruses affected humans (hCoVs), with estimated emergence occasions between 50 and 700 years ago [4,5]. These coronaviruses include two betacoronaviruses, OC43 and HKU1, which are of the same genus as SARS-CoV-1, SARS-CoV-2, Ac2-26 and MERS-CoV, and two alphacoronaviruses, 229E and NL63. The average age of 1st illness with OC43, HKU1, 229E, and NL63 is definitely 5 years [6], and individuals are frequently reinfected with the same computer virus over the course of their lives [79]. HCoV illness usually results in the common chilly, characterized by coryza, sore throat, headache, fever, and cough [10]. Like SARS-CoV-1 [11] and SARS-CoV-2 [12], hCoVs such as 229E develop antigenically, escaping immunity induced against earlier circulating strains [13]. Multiple unique lineages circulate, with two known lineages each of HKU1 and OC43. HCoVs OC43, HKU1, 229E, and NL63 are thought to impact populations globally, although variation has been explained in seroprevalence between the Americas, Africa, and Europe [14,15]. Given the recent SARS-CoV-1, SARS-CoV-2, and MERS-CoV spillovers, why are there not more circulating endemic hCoVs? It has been suggested that existing populace immunity could restrict entrance of novel coronaviruses [5]. Several Ac2-26 early studies during the COVID-19 pandemic explored whether hCoVs modulate SARS-CoV-2 illness and disease risk and clarify reduced severity of COVID-19 in children compared to adults [16]. You will find cross-reactive epitopes between the hCoVs and SARS-CoV-2 spike, especially in the S2 section [16,17]. Studies in adults and mice showed minimal effect of prior hCoV illness on SARS-CoV-2 illness risk [18,19], although recent illness may protect against a COVID-19 case [20,21]. However, pre-pandemic samples from children and adolescents were found to have higher levels of cross-neutralizing SARS-CoV-2 antibodies than older individuals [22,23], although not in all studies [24]. Children also have higher pre-pandemic IgM reactions to SARS-CoV-2 and additional hCoVs, whereas antibodies to these antigens in the elderly were mainly IgA or IgG [18,25]. Additionally, young adults have been observed.